Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) was the recipient of some unusual options trading activity on Thursday. Stock investors acquired 1,505 put options on the stock. This is an increase of approximately Infinity compared to the typical daily volume of 0 put options.
Hedge funds and other institutional investors have recently modified their holdings of the company. Gerber Kawasaki Wealth & Investment Management acquired a new position in shares of Ironwood Pharmaceuticals during the 3rd quarter valued at about $170,000. Teacher Retirement System of Texas acquired a new position in shares of Ironwood Pharmaceuticals during the 2nd quarter valued at about $192,000. Strs Ohio increased its holdings in shares of Ironwood Pharmaceuticals by 63.1% during the 2nd quarter. Strs Ohio now owns 10,600 shares of the biotechnology company’s stock valued at $200,000 after acquiring an additional 4,100 shares during the last quarter. Ameritas Investment Partners Inc. increased its holdings in shares of Ironwood Pharmaceuticals by 5.8% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 11,821 shares of the biotechnology company’s stock valued at $223,000 after acquiring an additional 648 shares during the last quarter. Finally, KCG Holdings Inc. increased its holdings in shares of Ironwood Pharmaceuticals by 20.5% during the 1st quarter. KCG Holdings Inc. now owns 14,270 shares of the biotechnology company’s stock valued at $243,000 after acquiring an additional 2,428 shares during the last quarter.
Shares of Ironwood Pharmaceuticals (NASDAQ IRWD) traded down $1.07 during trading on Monday, reaching $16.25. The company had a trading volume of 2,870,134 shares, compared to its average volume of 1,305,195. The company has a debt-to-equity ratio of -22.31, a current ratio of 4.87 and a quick ratio of 4.86. Ironwood Pharmaceuticals has a 1 year low of $13.43 and a 1 year high of $19.94.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.07. Ironwood Pharmaceuticals had a negative return on equity of 645.22% and a negative net margin of 48.89%. The company had revenue of $86.80 million for the quarter, compared to analyst estimates of $73.59 million. During the same period in the prior year, the firm posted ($0.18) EPS. The business’s revenue was up 31.3% compared to the same quarter last year. research analysts forecast that Ironwood Pharmaceuticals will post -1.12 earnings per share for the current year.
IRWD has been the topic of a number of analyst reports. Credit Suisse Group started coverage on shares of Ironwood Pharmaceuticals in a research report on Monday, November 27th. They issued a “buy” rating and a $19.00 price objective on the stock. ValuEngine lowered Ironwood Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, November 14th. BidaskClub downgraded Ironwood Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Wednesday, August 9th. Cowen set a $20.00 price objective on Ironwood Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, August 21st. Finally, Morgan Stanley reissued a “hold” rating on shares of Ironwood Pharmaceuticals in a research note on Monday. One analyst has rated the stock with a sell rating, seven have given a hold rating and five have assigned a buy rating to the company’s stock. Ironwood Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $18.38.
ILLEGAL ACTIVITY WARNING: This piece of content was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/12/04/traders-purchase-large-volume-of-put-options-on-ironwood-pharmaceuticals-irwd.html.
Ironwood Pharmaceuticals Company Profile
Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.
Receive News & Ratings for Ironwood Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.